Suspended

Signos mHealth Platform for Non-Insulin Dependent Type 2 Diabetes: Weight and Blood Glucose Management

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to help manage weight and blood glucose levels in individuals with non-insulin dependent type 2 diabetes using the Signos mHealth Platform, with primary focus on app engagement, changes in weight, and glucose metrics via Continuous Glucose Measurement (CGM).

What is being tested

Continuous Glucose Monitor Device

Device
Who is being recruted

Body Weight+18

+ Body Weight Changes

+ Diabetes Mellitus

Over 18 Years
+18 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: May 2023
See protocol details

Summary

Principal SponsorSignos Inc
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 11, 2023

Actual date on which the first participant was enrolled.

This study focuses on individuals with non-insulin dependent type 2 diabetes. It aims to improve their general wellness, body weight, and composition using a continuous glucose monitor (CGM) and a mobile health application called Signos. The study is designed to be low risk for participants. The importance of this research lies in its potential to enhance the management of type 2 diabetes, a condition that affects many people worldwide and requires effective strategies for maintaining a healthy lifestyle. Participants in this study will use the Signos app to log their meals and exercises, and complete activities. The study will measure their engagement with the app. Additionally, the study will track changes in participants' weight and glucose levels. Glucose will be monitored using a CGM, which provides continuous measurements. These measurements will help evaluate the effectiveness of the app and CGM in managing type 2 diabetes.

Official TitleUse of Signos mHealth Platform in Participants With Non-Insulin Dependent Type 2 Diabetes: Weight and Blood Glucose
NCT05874635
Principal SponsorSignos Inc
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20000 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Body WeightBody Weight ChangesDiabetes MellitusDiabetes Mellitus, Type 2Endocrine System DiseasesHyperglycemiaHyperinsulinismInsulin ResistanceMetabolic DiseasesNutrition DisordersNutritional and Metabolic DiseasesObesitySigns and SymptomsPathological Conditions, Signs and SymptomsWeight LossGlucose IntoleranceMetabolic SyndromeOvernutritionGlucose Metabolism DisordersOverweightObesity, Abdominal

Criteria

9 inclusion criteria required to participate
Medical diagnosis of Type 2 Diabetes; determined by review of subject-provided most recent Hg A1c.
Subject is under current care of a primary care provider or specialist
Clearance by medical provider to participate in diet, physical activity, and lifestyle changes
18 years and above
Show More Criteria
9 exclusion criteria prevent from participating
Medical diagnosis of Type 1 Diabetes
Type 2 Diabetes currently using insulin or most recent A1c ≥10%
Severe hypoglycemia <54 mg/dl resulting in seizure or unconsciousness, or requiring assistance/EMS/hospitalization - within 3 months prior to enrollment
Current medical diagnosis of an eating disorder (such as anorexia nervosa or bulimia)
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
For all consented participants, the Signos app will use CGM data to provide recommendations customized to users for promoting general health and wellness.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Signos

Palo Alto, United StatesOpen Signos in Google Maps
SuspendedOne Study Center